by Terry Myerson, CEO | Mar 8, 2022 | News
Today in a keynote at ViVE, I unveiled the Truveta platform for the first time with its first public demonstration. While preparing for this keynote, I reflected on how far our team, and our members, have come in the last two years, amidst the backdrop of the COVID-19...
by Truveta Research | Mar 8, 2022 | Research, Research Insights
After looking at the Truveta COVID-19 dashboard, our Research Team was curious about the breakthrough rates for specific disease types and how they compared between fully vaccinated individuals with and without booster shots. The team took the data in the dashboard...
by Truveta Research | Feb 24, 2022 | Research, Research Insights
Rates of myocarditis, pericarditis, and other cardiac conditions have been reported both during the acute phase of Covid-19 infection and up to 12-months post infection. Since this is American Heart Month, we wanted to learn more. So, we asked two key questions of a...
by Truveta Research | Feb 3, 2022 | Research, Research Insights
As we shared in our latest Truveta Platform insights last week, the COVID-19 Omicron variant has highlighted the positive impact of vaccinations and boosters in preventing hospitalization. Thus, we wanted to shed light on the percentage of people who are fully...
by Truveta Research | Jan 28, 2022 | Research, Research Insights
Just last week marked the two-year anniversary of the first case of COVID-19 in the United States, discovered by our health system member Providence. It’s hard to believe that it’s been two years, and just this past month we’ve experienced the highest number of daily...
